MorphoSys (ETR:MOR – Get Rating) has been assigned a €11.00 ($11.70) price target by investment analysts at JPMorgan Chase & Co. in a report issued on Thursday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price target suggests a potential downside of 31.85% from the company’s previous close.
Several other equities analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft set a €13.00 ($13.83) price target on shares of MorphoSys in a research note on Friday, November 25th. The Goldman Sachs Group set a €12.00 ($12.77) price objective on MorphoSys in a report on Tuesday, January 3rd. Finally, Morgan Stanley set a €12.50 ($13.30) price objective on MorphoSys in a report on Friday, January 6th.
MorphoSys Stock Performance
Shares of MorphoSys stock opened at €16.14 ($17.17) on Thursday. The firm has a market capitalization of $551.34 million, a P/E ratio of -0.65, a P/E/G ratio of 0.06 and a beta of 0.70. MorphoSys has a 52 week low of €11.81 ($12.56) and a 52 week high of €27.87 ($29.65). The company has a quick ratio of 3.49, a current ratio of 3.76 and a debt-to-equity ratio of 231.51. The firm’s 50 day moving average is €16.59 and its two-hundred day moving average is €17.69.
About MorphoSys
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
Read More
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
- Taiwan Semiconductor Manufacturing Expanding in the West
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.
